POLPHARMA-BIOLOGICS
21.1.2021 10:43:11 CET | Business Wire | Press release
European biotechnology company Polpharma Biologics has unveiled a new logo and corporate message as part of an extensive rebranding initiative.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005383/en/
Dr Joerg Windisch, CEO of Polpharma Biologics, said “Our new brand represents our passion and dedication to innovation, we utilize the latest technology and cutting-edge techniques to discover and advance ground breaking biologics to the clinic, whether this is our own pipeline or that of our partners.
The industry is rapidly reducing the time to develop and manufacture new molecules, this is down to significant improvements in automation with many previously time consuming steps replaced with equipment that can analyze thousands of samples in minutes incredibly accurately. Throughout our entire process from early stage discovery, through cell line development and process development and to fill finish we have adopted the very latest technology to ensure we can offer the best timelines and most comprehensive analytics to generate the highest quality biologic drugs, our new brand represents our commitment to this innovation.”
Dr Windisch, continued “We are also launching our new value proposition, “We Care”, this represents our unwavering dedication to the patients that need our products and our commitment to honesty and transparency in all our interactions. All our colleagues carry these values through all the work they do and in all our cooperation with partners. We all share the same goal – delivering safe and effective medicines to patients.”
The new brand and values launch come after a year of significant growth at Polpharma Biologics, it has brought its Utrecht research and development site, formerly Bioceros, and its Warsaw manufacturing site under the Polpharma Biologics brand, and significantly expanded its workforce by over 250 employees.
Much of the new recruitment has taken place at their new clinical and commercial manufacturing site in Warsaw, which began construction in 2018. It has reached a significant milestone with the installation of its first bioreactor suite which contains twin 2000 L SUBs. The suite is now under validation and will be suitable for the manufacture of clinical and commercial mammalian products, it is expected to be ready for its first production run in mid-2021. This is one of 5 manufacturing suites currently planned for the site which also contains research and process development laboratories.
Frank Ternes, Global Head of CDMO commented “The combination of our new brand and installation of new bioreactors brings us closer to our ambition to be an industry-leading biotechnology company, with a world-class offering to help partners take their products rapidly to market with the maximum chance of success. Polpharma Biologics now has the ability to offer a full range of solutions for both mammalian and microbial from discovery to commercial supply for both drug substance and drug product.”
-ENDS-
About Polpharma Biologics
Polpharma Biologics is a European biopharmaceutical company focused on the development and manufacture of biosimilar and novel biologic drugs. Polpharma Biologics operates across centers of excellence in Poland and the Netherlands providing fully integrated solutions along the biopharmaceutical value chain. Polpharma Biologics offers antibody discovery and optimization, cell line development, product and process development and clinical and commercial scale manufacturing to support the development of its proprietary portfolio of products and the provision of high quality contract development and manufacturing services to industry partners around the globe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210121005383/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs to Acquire U.S. Rare Earth and Critical Minerals Company Powering Defense and National Security14.5.2026 14:01:00 CEST | Press release
Proposed Acquisition Would Position Mobix Labs Inside Strategic U.S. Supply Chains Powering Defense, National Security, and AI Infrastructure Mobix Labs, Inc. (Nasdaq: MOBX) today announced it has signed a non-binding Letter of Intent to acquire Special Project Delivery LLC ("SPD"), a strategic infrastructure platform building sovereign U.S. supply chains for rare earth elements, critical minerals, and energy storage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514342224/en/ U.S.A F-35 Lightning II The proposed acquisition would expand Mobix Labs — already a supplier to advanced U.S. and allied defense and aerospace systems — directly into one of the world's most strategically important industrial sectors. Key Facts at a Glance~418 kilogramsof rare earth materials are estimated to be used in each F-35 Lightning II. ~4,500 kilogramsof rare earth materials are estimated to be used in each Virginia-class nuclear submarine
Enterprise AI Hits the Wall: NTT DATA Research Reveals Growing Privacy and Sovereignty Barriers14.5.2026 14:00:00 CEST | Press release
Demands for privacy and sovereignty expose limits of architectures built for centralized and borderless data flows. Data jurisdiction has become a core design parameter, shifting away from globally integrated systems to regionally bounded architectures. Organizations that redesign early are gaining a measurable edge in AI readiness and scale. NTT DATA, a global leader in AI, digital business and technology services, today released new research showing that enterprise AI is outgrowing the architecture and infrastructure beneath it as data privacy and sovereignty requirements tighten. The research finds a widening split between enterprises that are redesigning AI for control, locality and security, and organizations still layering AI into environments that were not built to support these requirements. For years, enterprise architecture moved data across systems, clouds, applications and borders with increasing speed and efficiency. AI is exposing the limits of that model. Sensitive data
Mary Kay Launches Global Social Squad Program to Empower the Next Generation of Digital Beauty Leaders14.5.2026 14:00:00 CEST | Press release
A Global Program Connecting 70+ Emerging Creators Among Independent Beauty Consultants with Digital Education, Mentorship, And Real‑World Beauty Brand Experience. Mary Kay Inc., a global leader in beauty and entrepreneurship, announces the launch of its Global Social Squad (GSS) Pilot Program – a groundbreaking initiative designed to empower Mary Kay Independent Beauty Consultants (IBCs) as dynamic digital brand advocates and next-generation social media storytellers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514978222/en/ The Global Social Squad ignites a diverse and talented group of 73 Mary Kay Independent Beauty Consultants with representation across 15 markets in four regions: North America, Asia Pacific, Latin America, and Europe. These digital leaders create engaging, high-quality content, participate in global campaign activations, and share practical social media strategies with their communities and other I
Vista Equity Partners Establishes Abu Dhabi Office14.5.2026 14:00:00 CEST | Press release
Securing Full Regulatory Authorization from ADGM deepens Vista’s commitment to the Middle East and expands the firm’s global platform for enterprise software investing Vista Equity Partners (“Vista”), a global technology investor that specializes in enterprise software, today announced the opening of its new office in Abu Dhabi within ADGM, the city’s international financial center. VEPM Middle East Limited has received full authorization from ADGM’s Financial Services Regulatory Authority (FSRA), enabling the firm to advise on investments and arrange deals in investments across the region. The Abu Dhabi office reflects Vista’s expanded strategic presence in the Middle East and the region’s increasingly central role in global technology investment and innovation. Established in 2013, ADGM has emerged as one of the world’s leading financial centers, connecting global investors with regional opportunities. Vista joins a growing community of leading global investment firms that have estab
Eighteen48 Partners Announces First Close of Eighteen48 Private Equity Fund I at €175 million14.5.2026 13:56:00 CEST | Press release
Eighteen48 Partners today announced the first close of Eighteen48 Private Equity Fund I (the “Fund”) at €175 million. The Fund, which is targeting €350 million, is focused on European middle-market buyout transactions sourced through Independent Sponsors. Since 2020 Eighteen48 Partners have deployed more than €200 million into this strategy, which aims to provide investors with diversified exposure to off-market sourced transactions. The first close was supported by significant re-up commitments from Eighteen48 clients as well as commitments from institutions, family offices and UHNWs, underscoring the strength of the firm’s platform, track record and experience as well as growing momentum in the Independent Sponsor space. Julien Sevaux, Founding Partner and CEO, commented: “We are increasingly excited by the opportunity in the growing independent sponsor segment of European private equity - a corner of the market we believe remains largely overlooked by investors yet offers compelling
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom